Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
- 20 October 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 51 (12), 2181-2187
- https://doi.org/10.3109/10428194.2010.524329
Abstract
High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p < 0.001). The only predictor of survival was cardiac stage (p < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.Keywords
This publication has 25 references indexed in Scilit:
- High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysisTransplantation and Cellular Therapy, 2010
- Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosisAmerican Heart Journal, 2009
- Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomaBone Marrow Transplantation, 2008
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisNew England Journal of Medicine, 2007
- Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)Bone Marrow Transplantation, 2007
- Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosisInternal Medicine Journal, 2007
- AmyloidosisBest Practice & Research Clinical Haematology, 2005
- Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateBone Marrow Transplantation, 2004
- High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosisBone Marrow Transplantation, 2001
- Encephalopathy complicating high-dose melphalanBone Marrow Transplantation, 1999